Passage Bio Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Passage Bio Inc (PASG) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Passage Bio Inc vs Its Competitors
- Scale: Passage Bio Inc ranks #135 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Passage Bio Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Passage Bio Inc | - | - | - | Yes |
| Competitors combined (16) | ||||
| High-Confidence Competitors (15) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PASG Stock Performance relative to its Competitors
PASG Stock Performance relative to High-Confidence Competitors
PASG Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Contextlogic Inc | 282.9% | Outperformed |
| 2 | 4d Molecular Therapeutics Inc | 282.9% | Outperformed |
| 3 | Taysha Gene Therapies Inc | 282.9% | Outperformed |
| 4 | Denali Therapeutics Inc | 282.9% | Outperformed |
| 5 | Protalix Biotherapeutics inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Passage Bio Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Passage Bio Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Passage Bio Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Passage Bio Inc | 14.90 | - |
| Gsk Plc | 100,495.97 | 43,093.89 |
| Takeda Pharmaceutical Company Limited | 29,441.62 | 29,183.90 |
| Crispr Therapeutics Ag | 5,380.18 | 13.39 |
| Denali Therapeutics Inc | 3,927.99 | 110.69 |
| Taysha Gene Therapies Inc | 1,819.39 | 8.10 |
| SUBTOTAL | 146,683.12 | 72,865.04 |
Sign in to see all competitors of Passage Bio Inc .
Sources: Passage Bio Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Passage Bio Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Passage Bio Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Prevail Therapeutics Inc. | Named by the company | 85% |
| GlaxoSmithKline | Named by the company | 85% |
| uniQure N.V. | Named by the company | 85% |
| Takeda Pharmaceutical Company Limited | Named by the company | 85% |
| Denali Therapeutics | Named by the company | 85% |
| Alector, Inc. | Named by the company | 85% |
| Eli Lilly & Co | Named by the company | 85% |
| Latus Bio, Inc. | Named by the company | 85% |
| Syncona Limited | Named by the company | 85% |
| Alkermes plc | Named by the company | 85% |
| AviadoBio | Named by the company | 85% |
| Neurogene Inc. | Named by the company | 85% |
| Shape Therapeutics Inc. | Named by the company | 85% |
| AcuraStem Inc. | Named by the company | 85% |
| Astellas | Named by the company | 85% |
| Evox Therapeutics Ltd | Named by the company | 85% |
| Lysogene, S.A. | Named by the company | 85% |
| QurAlis Corporation | Named by the company | 85% |
| Applied Genetic Technologies Corporation | Named by the company | 85% |
| Kyowa Kirin Co., Ltd. | Named by the company | 85% |
| Orchard Therapeutics plc | Named by the company | 85% |
| Sio Gene Therapies, Inc. | Named by the company | 85% |
| Voyager Therapeutics, Inc. | Named by the company | 85% |
| Astellas Pharma Inc. | Named by the company | 85% |
| Forge Biologics Inc. | Named by the company | 85% |
| National Institutes of Health | Named by the company | 85% |
| QurAlis Therapeutics | Named by the company | 85% |
| Transposon Therapeutics, Inc. | Named by the company | 85% |
| Crispr Therapeutics Ag | Named by the company | 85% |
| Arkuda Therapeutics, Inc. | Named by the company | 85% |
| Medicines Co | Named by the company | 85% |
| Bluebird Bio Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Passage Bio Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Passage Bio Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Uniqure N v | Single Reportable Segment 100.00 % |
| Editas Medicine Inc | Reportable 100.00 % |
| Protalix Biotherapeutics inc | Single Reportable Segment 100.00 % |
| Voyager Therapeutics Inc | Single reportable segment 100.00 % |
| Sangamo Therapeutics Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Passage Bio Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Passage Bio Inc | 15 | - | -1,337,481 |
| Gsk Plc | 100,496 | 169,660,977 | 32,662,867 |
| Takeda Pharmaceutical Company Limited | 29,442 | 620,934 | 14,657 |
| Crispr Therapeutics Ag | 5,380 | 66,627 | -2,244,473 |
| Denali Therapeutics Inc | 3,928 | 220,068 | 1,962 |
| Taysha Gene Therapies Inc | 1,819 | 81,798 | -1,511,444 |
| PEERS TOTAL | 146,668 | 1,458,584 | 147,238 |
Passage Bio Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| 4d Molecular Therapeutics Inc | JP 97.05 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Passage Bio Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Passage Bio Inc's industry classification, broader than the peer set above. Market cap in millions of $.Passage Bio Inc ranks #135 of 159 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,324, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 230,460 | 25.95 % |
| 2 | Gilead Sciences Inc | 188,041 | 21.17 % |
| 3 | Moderna Inc | 80,977 | 9.12 % |
| 4 | Argenx Se | 64,092 | 7.22 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 135 | Passage Bio Inc | 15 | 0.00 % |
Market cap and industry share for the rest of Passage Bio Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-29.
Passage Bio Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 130 | In8bio Inc | 25 | -44.10 % |
| 131 | Cel sci Corporation | 22 | -80.84 % |
| 132 | Tradeup Acquisition Corp | 20 | -60.17 % |
| 133 | Jasper Therapeutics Inc | 18 | -73.77 % |
| 134 | Dyadic International Inc | 1,234 | 12.3% |
| 135 | Passage Bio Inc | 15 | -39.00 % |
| 136 | Genenta Science S p a | 1,234 | 12.3% |
| 137 | Zivo Bioscience Inc | 1,234 | 12.3% |
| 138 | Biocardia Inc | 1,234 | 12.3% |
| 139 | Brainstorm Cell Therapeutics inc | 1,234 | 12.3% |
| 140 | Pluri Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Passage Bio Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-29. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Passage Bio Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (93 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.7x | - |
| EV / EBITDA | - | 21.3x | - |
| P/B | 1.0x | 5.1x | -4.1x |
| Return on Equity | -218.59 % | industry aggregate | -215.16 % |
| Return on Invested Capital | -87.68 % | -6.17 % (avg) | -81.51 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Passage Bio Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| Return on Invested Capital | -16.18 % | -27.30 % | -27.59 % | -35.78 % | -37.65 % | -55.78 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Passage Bio Inc's BCG Growth-Share Matrix
Relative market share (vs Passage Bio Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Passage Bio Inc falls in the Question Mark quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 10.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Passage Bio Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,324 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Passage Bio Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Passage Bio Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Passage Bio Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Passage Bio Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Passage Bio Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 215.2 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-16.9% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Passage Bio Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Passage Bio Inc | 1.82 | 1.90 | - |
| Gsk Plc | 0.16 | 0.82 | 0.87 |
| Takeda Pharmaceutical Company Limited | 0.09 | 0.56 | 0.58 |
| Crispr Therapeutics Ag | 2.51 | 16.26 | 0.16 |
| Denali Therapeutics Inc | 2.28 | 9.16 | - |
| Taysha Gene Therapies Inc | 13.32 | 13.51 | 0.19 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Passage Bio Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Passage Bio Inc | Q2 2026 | - | - |
| Gsk Plc | Q4 2025 | +7.5 % | +120.0 % |
| Takeda Pharmaceutical Company Limited | Q1 2025 | +0.1 % | -30.2 % |
| Crispr Therapeutics Ag | Q2 2026 | +1,041.4 % | - |
| Denali Therapeutics Inc | Q2 2026 | - | - |
| Taysha Gene Therapies Inc | Q2 2026 | - | - |
| PEERS TOTAL | +4.4 % | +114.0 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Passage Bio Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Passage Bio Inc | Q2 2026 | - | - |
| Gsk Plc | Q4 2025 | +7.2 % | -0.6 % |
| Takeda Pharmaceutical Company Limited | Q1 2025 | +3.1 % | +6.6 % |
| Crispr Therapeutics Ag | Q2 2026 | - | +453.8 % |
| Denali Therapeutics Inc | Q2 2026 | - | +592.0 % |
| Taysha Gene Therapies Inc | Q2 2026 | - | - |
Passage Bio Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Passage Bio Inc | - | - | - |
| Gsk Plc | 10.09% | 44.94% | 38.67% |
| Takeda Pharmaceutical Company Limited | 0.76% | 0.97% | 1.56% |
| Crispr Therapeutics Ag | - | - | - |
| Denali Therapeutics Inc | 0.09% | 0.09% | 0.11% |
| Taysha Gene Therapies Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Passage Bio Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Passage Bio Inc | - | - |
| Gsk Plc | 17.58 | 2.33 |
| Takeda Pharmaceutical Company Limited | 42.74 | 1.01 |
| Crispr Therapeutics Ag | - | 401.75 |
| Denali Therapeutics Inc | - | 35.49 |
| Taysha Gene Therapies Inc | - | 224.67 |
| PEERS AVERAGE | 20.04 | 2.01 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.